This suggests that there might be little if any functional effect of the common CYP17 polymorphisms, at least among postmenopausal women, although there is a possibility that there might exist other variants and haplotypes associated with hormone levels and risk of breast cancer. This evidence concerns the gene CYP17A1 and breast cancer.